Abstract
Amoebiasis, a disease characterized by abdominal pain, loose motion, and blood-containing feces, is caused by a unicellular protozoan parasite Entamoeba histolytica. It afflicts nearly 500 million people worldwide and is the second leading cause of death from a parasitic infection in children under 5 years of age. The cysts are the infective stages, and the infection spreads through ingestion of mature cysts in fecally contaminated food and drinking water or by hands from an infected person. A majority of infected persons often remain asymptomatic; however, in some cases, infection can lead to severe clinical complications like dysentery and amoebic liver abscesses. Though metronidazole (a 5-nitroimidazole) continues to be a drug of choice for the treatment of amoebic dysentery, for its complete cure, a combination of a tissue amoebicide (usually a 5-nitroimidazole) and a luminal amoebicide (e.g., diloxanide furoate) is required. Unfortunately, the occurrence of E. histolytica strains resistant to metronidazole, its potential carcinogenicity, and a strong metallic taste after a few days of use are some of its big limitations. Satranidazole, a novel 5-nitroimidazole discovered and developed in India, is now available in several formulations. Nevertheless, the treatment of amoebiasis continues to remain far from satisfactory, and there is a strong and compelling need to discover and develop novel and improved antiamoebic drugs. Further, the availability of clean drinking water, proper sanitation, and good personal hygiene including handwashing will continue to remain important driving factors in tackling the problem of amoebiasis. This overview summarizes the history, life cycle, currently available drugs, and, more importantly, the progress on the discovery of novel antiamoebic agents and various preventive measures for the control of amoebiasis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abid M, Azam A (2006) Synthesis, characterization and antiamoebic activity of 1-(thiazolo[4,5-b]quinoxaline-2-yl)-3-phenyl-2-pyrazoline derivatives. Bioorg Med Chem Lett 16:2812–2816
Abid M, Husain K, Azam A (2005) Synthesis and antiamoebic activity of new oxime ether derivatives containing 2-acetylpyridine/2-acetylfuran. Bioorg Med Chem Lett 15:4375–4379
Abid M, Bhat AR, Athar F, Azam A (2009) Synthesis, spectral studies and antiamoebic activity of new 1-N-substituted thiocarbamoyl-3-phenyl-2-pyrazolines. Eur J Med Chem 44:417–425
Adagu IS, Nolder D, Warhurst DC, Rossignol JF (2002) In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J Antimicrob Chemother 49:103–111
Ali V, Nozaki T (2007) Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by “amitochondriate” protozoan parasites. Clin Microbiol Rev 20:164–187
Aslam S, Musher DM (2007) Nitazoxanide: clinical studies of a broad-spectrum anti-infective agent. Future Microbiol 2:583–590
Athar F, Husain K, Abid M, Agarwal SM, Coles SJ, Hursthouse MB, Maurya MR, Azam A (2005) Synthesis and antiamoebic activity of gold (I), ruthenium (II) and copper (II) complexes of metronidazole. Chem Biodivers 2:1320–1330
Azam A, Agarwal SM (2007) Targeting Amoebiasis: status and developments. Current Bioactive compounds 3:121–133
Azam A, Peerzada MN, Ahmad K (2015) Parasitic diarrheal disease: drug development and targets. Front Microbiol 6:1–12
Bharti N, Shailendra, Coles SJ, Hursthouse MB, Mayer TA, Gonzalez Garza MT, Cruz-Vega DE, Mata-Cardenas BD, Naqvi F, Maurya MR, Azam A (2002) Synthesis, crystal structure and enhancement of the efficacy of metronidazole against Entamoeba histolytica by complexation with palladium (II), platinum (II) or copper (II). Helv Chim Acta 85:S2704–S2712
Bhat AR, Athar F, Azam A (2009a) Bis-pyrazolines: synthesis, characterization and antiamoebic activity as inhibitors of growth of Entamoeba histolytica. Eur J Med Chem 44:426–431
Bhat AR, Athar F, Azam A (2009b) New derivatives of 3,5-substituted-1,4,2-dioxazoles: synthesis and activity against Entamoeba histolytica. Eur J Med Chem 44:926–936
Budakoti A, Bhat AR, Athar F, Azam A (2008) Syntheses and evaluation of 3-(3-bromo phenyl)-5-phenyl-1-(thiazolo [4,5-b] quinoxaline-2-yl)-2-pyrazoline derivatives. Eur J Med Chem 43:1749–1757
Calzada F, Alanis AD, Meckes M, Tapia-Contreras A, Cedillo-Rivera R (1998) In vitro susceptibility of Entamoeba histolytica and Giardia lamblia to some medicinal plants used by the people of southern Mexico. Phytother Res 12:70–72
Calzada F, Velazquez C, Cedillo-Rivera R, Esquivel B (2003a) Antiprotozoal activity of the constituents of Teloxys graveolens. Phytother Res 17:731–732
Calzada F, Barbosa E, Cedillo-Rivera R (2003b) Antiamoebic activity of benzyl glucosinolate from Lepidium virginicum. Phytother Res 17:618–619
Campos-Rodriguezp R, Jarillo-Luna A (2005) The pathogenicity of Entamoeba histolytica is related to the capacity of evading innate immunity. Parasite Immunol 27:1–8
Chatterjee DK, Iyer SN, Venugopalan B, Raether W (1997) Antiamoebic activity of 3,3′-fluro-4,4′-di-(pyrrolidine-2-ylidene amino)-diphenyl (liroldine), against experimentally infected intestinal and hepatic amoebiasis. Indian J Exp Biol 35:765–770
Debnath A, Parsonage D, Andrade RM, He C, Cobo ER, Hirata K, Chen S, García-Rivera G, Orozco E, Martínez MB, Gunatilleke SS, Barrios AM, Arkin MR, Poole LB, McKerrow JH, Reed SL (2012) A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat Med 18:956–962
Diamond LS (1961) Axenic cultivation of Entamoeba histolytica. Science 134:336–337
Ghosh S, Chan JM, Lea CR, Meints GA, Lewis JC, Tovian ZS, Flessner RM, Loftus TC, Bruchhaus I, Kendrick H, Croft SL, Kemp RG, Kobayashi S, Nozaki T, Oldfield E (2004) Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. J Med Chem 47:175–187
Hayat F, Azam A, Shin D (2016) Recent progress on the discovery of antiamoebic agents. Bioorg Med Chem Lett 26:5149–5159
Heredia RD, Fonseca JA, López MC (2012) Entamoeba moshkovskii perspectives of a new agent to be considered in the diagnosis of amoebiasis. Acta Trop 123:139
Hung CC (2007) Amoebiasis: current status in Australia. Med J Aust 187:372
Hung CC, Dar-Der Ji HYS, Lee YT, Hsu SY, Chang SY, Wu CH, Chan YH, Hsiao CF, Liu WC, Colebunders R (2008) Increased risk for Entamoeba histolytica infection and invasive Amebiasis in HIV seropositive men who have sex with men in Taiwan. PLoS Negl Trop Dis 2:e175
Husain K, Abid M, Azam A (2008) Novel Pd (II) complexes of 1-N-substituted 3-phenyl-2-pyrazoline derivatives and evaluation of antiamoebic activity. Eur J Med Chem 43:393–403
Imperato PJ (1981) A historical overview of amebiasis. Bull N Y Acad Med 57:175–187
Legator MS, Connor TH, Stoeckel M (1975) Detection of mutagenic activity of metronidazole and niridazole in body fluids of humans and mice. Science 188:1118–1119
Leitsch D, Kolarich D, Wilson IB, Altmann F, Duchene M (2007) Nitroimidazole action in Entamoeba histolytica: a central role for thioredoxin reductase. PLoS Biol 5:e211
Lopez-Vallejo F, Medina-Franco JL, Hernandez-Campos A, Rodrıguez-Morales S, Yepez L, Cedillo R, Castillo R (2007) Molecular modeling of some 1H-benzimidazole derivatives with biological activity against Entamoeba histolytica: a comparative molecular field analysis study. Bioorg Med Chem 15:1117–1126
Marshall SJ, Russell PF, Wright CW, Anderson MM, Phillipson JD, Kirby GC, Warhurst DC, Schiff PL Jr (1994) In vitro antiplasmodial, antiamoebic, and cytotoxic activities of a series of bisbenzylisoquinoline alkaloids. Antimicrob Agents Chemother 38:96–103
Ordaz-Pichardo C, Shibayama M, Villa-Trevino S, Arriaga-Alba M, Angeles E, de la Garza M (2005) Antiamoebic and toxicity studies of a carbamic acid derivative and its therapeutic effect in a hamster model of hepatic amoebiasis. Antimicrob Agents Chemother 49:1160–1168
Orozco E, Lopez C, Gomez C, Perez DG, Marchat L, Banuelos C, Delgadillo DM (2002) Multidrug resistance in the protozoan parasite Entamoeba histolytica. Parasitol Int 51:353–359
Peterson KM, Singh U, Petri WA Jr (2011) Enteric Amoebiasis. In: Guerrant R, Walker DH, Weller PF (eds) Tropical infectious diseases: principles, pathogens and practice, 3rd edn. Saunders Elsevier, Philadelphia, p 614
Petri WA Jr (2003) Therapy of intestinal protozoa. Trends Parasitol 19:523–526
Roder C, Thomson MJ (2015) Auranofin: repurposing an old drug for a golden new age. Drugs in R & D 15:13–20
Rogers L (1912) The rapid cure of amoebic dysentery and hepatitis by hypodermic injections of soluble salts of emetine. Br Med J 1:14–24
Rossignol JF, Kabil SM, El-Gohary Y, Younis AM (2007) Nitazoxanide in the treatment of amoebiasis. Trans R Soc Trop Med Hyg 101:1025–1031
Rustia M, Shubik P (1972) Induction of lung tumors and malignant lymphomas in mice by metronidazole. J Natl Cancer Inst 48:721–729
Seifert K, Duchene M, Wernsdorfer WH, Kollaritsch H, Scheiner O, Wiedermann G, Hottkowitz T, Eibl H (2001) Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob Agents Chemother 45:1505–1510
Sharma P, Sharma JD (2001) A review of plant species assessed in vitro for antiamoebic activity or both antiamoebic and antiplasmodial properties. Phytother Res 15:1–17
Sharma S, Athar F, Maurya MR, Azam A (2005a) Copper (II) complexes with substituted thiosemicarbazones of thiophene-2-carboxaldehyde: synthesis, characterization and antiamoebic activity against E. histolytica. Eur J Med Chem 40:1414–1419
Sharma S, Athar F, Maurya MR, Naqvi F, Azam A (2005b) Novel bidentate complexes of Cu (II) derived from 5-nitrofuran-2-carboxaldehyde thiosemicarbazones with antiamoebic activity against Entamoeba histolytica. Eur J Med Chem 40:557–562
Singh S, Husain K, Athar F, Azam A (2005a) Synthesis and antiamoebic activity of 3,7-dimethyl-pyrazolo[3,4-e][1,2,4]triazin-4-yl thiosemicarbazide derivatives. Eur J Med Chem 25:255–262
Singh S, Athar F, Azam A (2005b) Synthesis, spectral studies and in vitro assessment for antiamoebic activity of new cyclooctadiene ruthenium (II) complexes with 2-nitrothiophene-2-carboxaldehyde thiosemicarbazones. Bioorg Med Chem Lett 15:5424–5428
Singh S, Athar F, Maurya MR, Azam A (2006) Cyclooctadiene Ru (II) complexes of thiophene-2-carboxaldehyde-derived thiosemicarbazones: synthesis, characterization and antiamoebic activity. Eur J Med Chem 41:592–598
Singh S, Bharti N, Mohapatra PP (2009) Chemistry and biology of synthetic and naturally occurring Antiamoebic agents. Chem Rev 109:1900–1947
Stanley SL Jr (2003) Amoebiasis. Lancet 361:1025–1034
Stanley SL Jr (2006) Vaccines for amoebiasis: barriers and opportunities. Parasitology 133:81–86
Venugopalan B, Patel B, Karnik PJ, de Souza NJ, Chatterjee DK, Iyer N (1996) Synthesis of diphenyl bisamidines as potential amoebicides. Eur J Med Chem 1:485–488
Wassermann C, Hellberg A, Tannich E, Bruchhaus I (1999) Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron-containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase. J Biol Chem 274:26051–26056
Wright CW, Phillipson JD (1990) Natural products and the development of selective antiprotozoal drugs. Phytother Res 4:127–139
Wright CW, Bray DH, O’Neill MJ, Warhurst DC, Phillipson JD, Quetin Leclercq J, Angenot L (1991) Antiamoebic and antiplasmodial activities of alkaloids isolated from Strychnos usambarensis. Planta Med 57:337–340
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Mital, A. (2018). Amoebiasis Revisited. In: Singh, P. (eds) Infectious Diseases and Your Health. Springer, Singapore. https://doi.org/10.1007/978-981-13-1577-0_2
Download citation
DOI: https://doi.org/10.1007/978-981-13-1577-0_2
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-1576-3
Online ISBN: 978-981-13-1577-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)